0.89
+0.015(+1.72%)
Currency In USD
| Previous Close | 0.87 |
| Open | 0.87 |
| Day High | 0.89 |
| Day Low | 0.87 |
| 52-Week High | 4.11 |
| 52-Week Low | 0.72 |
| Volume | 1,536 |
| Average Volume | 61,075 |
| Market Cap | 11.08M |
| PE | -0.15 |
| EPS | -5.85 |
| Moving Average 50 Days | 0.9 |
| Moving Average 200 Days | 1.24 |
| Change | 0.02 |
If you invested $1000 in HOOKIPA Pharma Inc. (HOOK) since IPO date, it would be worth $6.32 as of October 24, 2025 at a share price of $0.885. Whereas If you bought $1000 worth of HOOKIPA Pharma Inc. (HOOK) shares 5 years ago, it would be worth $9.24 as of October 24, 2025 at a share price of $0.885.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock
GlobeNewswire Inc.
Jul 18, 2025 8:05 PM GMT
NEW YORK and VIENNA, July 18, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, “HOOKIPA”), a clinical-stage biopharmaceutical company developing next-generation immunotherapeutics for the treatment of cancer and serious infectious diseas
HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)
GlobeNewswire Inc.
Feb 20, 2025 4:42 PM GMT
NEW YORK and VIENNA, Austria, Feb. 20, 2025 (GLOBE NEWSWIRE) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF T
HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV
GlobeNewswire Inc.
Jan 30, 2025 12:00 PM GMT
HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of a curative regimen for human immunodeficiency virus (HIV) Under the collaboration agreement, HOOKIPA is r